http://www.csbioactive.com CsBioactive - The most researched brand of chondroitin sulfate es
Professor Jean-Pierre Pelletier will present the results of a clinical trial which provides evidence that patients receiving chondroitin sulfate treatment experience a lower risk of having to endure prosthetic surgery.]]>
• Dr. Vergés said that "this tool could be used to identify and to give personalized treatment to severe OA cases and to assess the risks of prosthetic surgery, which in turn will lead to significant savings in health care expenditure”.]]>
• The study’s results will be presented at the World Congress on Osteoarthritis, to be held in Barcelona, Spain, on April 25-29, 2012]]>
It is hosted in the condroprotection.es website, a dedicated portal for healthcare professionals who specialize in osteoarthritis.]]>
Osteoarthritis is a disease under-diagnosed among menopausal women that decreases their quality of life

It has been proposed a new classification of primary and/or idiopathic osteoarthritis that will take into account the deficit of estrogens]]>
•The Spanish chemical-pharmaceutical company, which employs 386 workers, has more than 58 R&D projects currently under development.]]> Their new project focus on the research and validation of imaging and biochemical biomarkers used to diagnose knee osteoarthritis (OA) prior to the development of symptoms, to identify patient’s profiles, and to predict disease progression.

Biomarkers could be used to measure the efficacy of treatments, thus enabling the National Health System to save money.

The Foundation of the National Institutes of Health guarantees that the aim of this partnership is the improvement of the quality of life of OA patients by means of early diagnosis and personalized treatment.

]]>
Osteoarthritis affects more than seven million people in Spain. This disease is one of the most common causes of permanent incapacity to work.]]>
Proven efficacy and high security profile, major conclusions of his paper]]> The ‘Osteoarthritis Agenda’ section will list the most important congresses dealing with this disease, such as the World Congress on Debates and Consensus in Bone, Muscle and Joint Diseases that is going to be held the coming 20th of January.]]> Conference on psoriatic osteoarthritis and other chronic inflammatory diseases]]> It is estimated that by 2020 osteoarthritis will become the fourth most common cause of disability because of the population’ longer life expectancy and progressive ageing.
Apart from ageing, the other factors leading to the development of osteoarthritis are obesity, genetic predisposition and joint overuse.
The role of family physicians is fundamental in the early detection of osteoarthritis because they are the medicine professionals most frequently consulted by the general population.]]>
Dr. Villalón, head of the Club Atlético de Madrid medical department, points out that the chances of a sportsperson of developing osteoarthritis increase after suffering a knee trauma.

"Chondroprotection” would be the array of measures aiming at preventing, delaying, stabilizing, repairing and even completely eliminating the damage caused by osteoarthritis. ]]>
The aim of the MOVES project (Multicenter Osteoarthritis InterVEntion trial with Sysadoas) is to contribute further evidence of the efficacy and security of the combination of chondroitin sulfate and glucosamine in the treatment of knee osteoarthritis patients with moderate to severe pain.]]>
Primary care physicians should play a key role in the diagnosis and treatment of osteoarthritis in order to improve its symptoms (pain, functional disability) and to delay its progression]]>
Gynecologists are now beginning to diagnose and treat post menopausal osteoarthritis.

Osteoarthritis in menopausal women is under diagnosed, and affects negatively their quality of life.]]>
* The objectives of the PACAP are to encourage healthy lifestyles, disseminate information related to health issues, and to improve the quality of life and the social welfare level of the population.]]>
According to the World Health Organization (WHO), osteoarthritis is the fourth most common cause of loss of Quality Adjusted Life Years. ]]>
They will sponsor two symposiums, one on personalized medicine, and another on the treatment of chronic osteoarthritis

The city of Barcelona, in collaboration with Bioibérica, will host OARSI2012.]]>
Professor Jean-Pierre Pelletier from Montreal, Canada, presented the results of a clinical trial that confirm the disease-modifying effects of chondroitin sulphate. These results have also been presented in an article published in the June issue of Annals of the Rheumatic Diseases. Spanish rheumatologist Francisco J. Blanco, from the Corunna hospital, confirmed the efficacy of the combination of chondroitin sulphate and glucosamine to combat osteoarthritis.

Dr. Virginia Byers Kraus from Durham, USA, determined that osteoarthritis has an important inflammatory aspect, thus redefining our concepts about that disease]]>
Rheumatologist Dr. Francisco Blanco Garcia presented in the XXXVII National Congress of the Spanish Society of Rheumatology (SER 2011), held in Malaga, the research project that is working on the development of that tool. Thirty-two research centres from all over Spain are participating in this project]]>